MetaCap

Ernexa Therapeutics (ERNA) vs Redhill Biopharma (RDHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Redhill Biopharma is the larger company by market cap ($4.2 million vs $3.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

ERNA versus RDHL key metrics
MetricERNARDHL
Share price$2.39$0.474
Market cap$3.90M$4.21M
1-day change+6.94%-2.07%
Forward P/E—15.80
EPS (TTM)$-14.03$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$71.50$2.14
52-week low$2.15$0.465
Distance from 52-week high-96.66%-77.85%
Average volume462.76K1.84M
Shares outstanding1.63M8.89M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

ERNA vs RDHL FAQ

Which is bigger, Ernexa Therapeutics or Redhill Biopharma?

Redhill Biopharma (RDHL) is larger, with a market capitalization of $4.21M compared with $3.90M for Ernexa Therapeutics (ERNA).

Are Ernexa Therapeutics and Redhill Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons